Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
SET and MYND domain-containing protein 3 is overexpressed in human glioma and contributes to tumorigenicity
First author：Bin Dai
Corresponding author：LIWEI ZHANG
essential_information
2015-11-01
Published articles
Journal：Oncology Reports
Publication type: Oncology Reports
IF(IF): 3.906
PMID: 26328527 Link To Pubmed Full text Download
Background And Purpose
Method
Here, we determined the expression of SMYD3 and assessed its clinical significance in human glioma.
Conclusion
These results showed that SMYD3 is overexpressed in human glioma and contributes to glioma tumorigenicity through p53. Therefore, SMYD3 may be a new potential therapeutic target for human malignant glioma.
Main results
We found that SMYD3 was overexpressed in human glioma but not in normal brain tissue. The level of SMYD3 protein expression in human glioma tissues was directly correlated with the glioma grade. The level of SMYD3 protein expression in human glioma tissues was inversely correlated with patient survival. Enforced SMYD3 expression promoted glioma LN-18 cell proliferation. Inhibition of SMYD3 expression in glioma T98G cells suppressed their anchorage‑independent growth in vitro and tumorigenicity in vivo. Furthermore, we found that SMYD3 regulated the expression of p53 protein, which is essential in SMYD3‑induced cell growth in glioma cells.